|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.India |
First Approval Date05 Jun 2013 |
/ Not yet recruitingPhase 1 A Phase 1, Open-label, Single Arm Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Saroglitazar Magnesium Dosed on Alternate Days in Subjects Having Moderate Hepatic Impairment with Cirrhosis Due to Cholestatic Liver Disease
Evaluating Pharmacokinetic and safety of Saroglitazar Magnesium 1 mg when dosed on alternate days in subjects having moderate hepatic impairment with cirrhosis due to cholestatic liver disease
A Multicenter, Open-Label, Extension Clinical Trial to Evaluate Safety and Efficacy of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis (PBC)
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
/ CompletedNot Applicable Evaluation of Glycaemic Index of test food(s) in Healthy Adult Human Subjects using ISO 26642 method. - Nil
100 Clinical Results associated with Zydus Wellness Ltd.
0 Patents (Medical) associated with Zydus Wellness Ltd.
100 Deals associated with Zydus Wellness Ltd.
100 Translational Medicine associated with Zydus Wellness Ltd.